Evotec Signs High Throughput Screening Collaboration with Alios Biopharma
News Jul 22, 2009
Evotec AG has announced collaboration with Alios Biopharma, Inc in the area of high throughput screening (HTS).
Alios BioPharma, Inc. is a biotechnology company that is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system.
Evotec will use its proprietary ultra-HTS platform and technology to screen a priority biological target for Alios. Evotec’s HTS technology has been developed in collaboration with its pharmaceutical partners Pfizer, Novartis and GSK. It combines an ultra sensitive detection technology with a miniaturized screening format. In addition, Alios will access Evotec’s high quality small molecule screening library for the screen.
Dr. Leonid Beigelman, Executive Vice President of Research, from Alios commented: “Evotec has compiled a small molecule screening library that provides excellent diversity and high quality. This, combined with their exceptional HTS technology makes them an ideal partner for screening our important target with the aim of finding high quality hits for our subsequent medicinal chemistry efforts.”
Evotec’s EVP, Business Development, Dr Mark Ashton commented on the collaboration: “We are pleased that Alios have chosen Evotec to provide HTS support for their important target. We are excited about identifying new hits for their program and supporting them in their quest for new treatments for virology diseases.”
No financial details are disclosed.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018